Controlled Substance Update
TO: All New York State Pharmacies
FROM: James Giglio, Director, Bureau of Narcotic Enforcement
DATE: September, 2006
SUBJECT: Controlled Substance Update
On August 16, 2006, a new law went into effect that made changes to the controlled substance schedules in section 3306 of the Public Health Law. The changes are summarized below. Where applicable, some common brand name pharmaceutical preparations containing the controlled substances are listed in bold:
Schedule II additions:
- Remifentanil (ie; Ultiva® Pwd for Injection)
- Chlorotestosterone (4-Chlorotestosterone)
- Dihydrotestosterone (4-Dihydrotestosterone;ie; Androgel-DHT® Gel)
- Testolactone (ie; Teslac® Tablets)
Schedule III additions:
- Ketamine (ie; Ketalar®, Ketalin®, Ketanest® injection) repealed from Schedule III (b) Stimulant and added to Schedule III (c) Depressant.
- Buprenorphine (ie; Buprenex® Injection, Suboxone® Tablet, Subutex® Tablet) repealed from Schedule V and added to Schedule III
Schedule IV additions:
- Dichloralphenazone (ie; Duradin®, Midrin®, Migratine®)
- Zaleplon (ie; Sonata®)
- Zopiclone (Eszopiclone) (ie; Lunesta®)
- Modafanil (ie; Provigil®)
- Sibutramine (ie; Meridia®)
- Butorphanol (ie; Stadol® Injection, Stadol NS® Nasal Spray)
The new law made no additions to schedule V.
NOTE: Pregabalin (ie; Lyrica®) is a Schedule V controlled substance under Title 21 of the Code of Federal Regulations. However, pregabalin is not scheduled as a controlled substance in New York under section 3306 of the Public Health Law.
The schedules of controlled substances and the controlled substance law and regulations may be viewed in their entirety online at: www.nyhealth.gov/professionals/narcotic